Central hypothyroidism is treated with the same hormone used for the more common primary form of the condition: levothyroxine, a synthetic version of thyroxine (T4). But nearly everything else about managing it differs. Because the problem originates in the pituitary gland or hypothalamus rather than the thyroid itself, the usual blood test doctors rely on to adjust doses becomes unreliable, safety precautions around other hormone deficiencies take on outsize importance, and dosing during pregnancy or infancy follows its own rules.
Why Treatment Demands a Different Approach
In primary hypothyroidism, the thyroid gland itself fails. The pituitary responds by pumping out more thyroid-stimulating hormone (TSH), and doctors use that elevated TSH reading as both a diagnostic flag and a dosing guide. Central hypothyroidism flips that logic. Here the pituitary or the hypothalamus is damaged or dysfunctional, so TSH production is already low or inappropriately normal. You can have genuinely low thyroid hormone levels while your TSH looks fine on paper. That disconnect is what makes diagnosis tricky and monitoring during treatment fundamentally different from the standard approach.
The causes range widely. Pituitary tumors and their surgical or radiation treatment are the most common acquired triggers in adults. Immune checkpoint inhibitor drugs used in cancer therapy have emerged as a significant newer cause, with one study finding central hypothyroidism in about 94% of patients who developed immune-related inflammation of the pituitary gland during treatment.1Endocrine-Related Cancer. Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns In children, genetic defects affecting pituitary development account for many cases, with mutations in the IGSF1 gene appearing to be one of the more frequently involved culprits.2PubMed. The multiple genetic causes of central hypothyroidism Regardless of the cause, though, the treatment backbone stays the same: daily levothyroxine.
The Safety Step That Cannot Be Skipped
Before starting levothyroxine in someone with central hypothyroidism, doctors must check whether the adrenal glands are also underperforming. Because the same pituitary damage that reduces TSH secretion can simultaneously impair the signal that tells the adrenal glands to produce cortisol, many patients with central hypothyroidism also have central adrenal insufficiency. Starting thyroid hormone replacement without first replacing cortisol can trigger a life-threatening adrenal crisis.3Pediatric Health, Medicine and Therapeutics. Current Screening Strategies for the Diagnosis of Adrenal Insufficiency in Children
The mechanism is straightforward: thyroid hormone speeds up cortisol metabolism. If your adrenals are already struggling to produce enough cortisol, adding levothyroxine burns through what little cortisol remains even faster. The result can be dangerously low blood pressure, severe dehydration, and collapse. This is not a theoretical concern. Case reports describe patients ending up in intensive care after levothyroxine was started without adrenal coverage.4Clinical Medicine. Adrenal insufficiency – recognition and management
There is an additional diagnostic wrinkle here. Adrenal insufficiency itself can cause a mild rise in TSH that mimics hypothyroidism. Replacing cortisol often brings the TSH back to normal on its own, sometimes removing the apparent need for levothyroxine entirely. So the sequence matters for both safety and accuracy: evaluate and treat adrenal function first, then reassess thyroid status once cortisol levels are stable.
Dosing and the Free T4 Target
Levothyroxine remains the standard medication for central hypothyroidism, just as it is for primary hypothyroidism. The drug provides a steady supply of T4, which the body’s own enzymes then convert into the more active T3 form as needed. A typical starting dose in adults is on the lower end and gets adjusted upward over weeks, particularly in older patients or those with heart disease, where ramping up too quickly can strain the cardiovascular system.
What sets central hypothyroidism apart is the monitoring target. In primary hypothyroidism, the goal is simple: adjust levothyroxine until TSH falls into a normal range, generally between about 1 and 2 mU/L.5SpringerLink / Adis. Optimizing treatment of hypothyroidism That approach does not work in central hypothyroidism, because TSH is already low or suppressed and does not respond to levothyroxine the way a healthy pituitary’s TSH would. In fact, TSH in many central hypothyroidism patients gets rapidly pushed down even further once levothyroxine is introduced.6European Thyroid Journal. 2018 European Thyroid Association (ETA) Guidelines on the Diagnosis and Management of Central Hypothyroidism
Instead, doctors rely on free T4 levels as the primary guide. The 2018 European Thyroid Association guidelines recommend aiming for free T4 in the mid to upper portion of the normal reference range.7The Journal of Clinical Endocrinology & Metabolism. Central Hypothyroidism: Pathogenic, Diagnostic, and Therapeutic Challenges This target reflects the observation that patients tend to feel and function best when free T4 sits comfortably above the midpoint rather than hovering near the lower boundary.
TSH is not entirely useless in all cases, though. In patients whose TSH was measurably above the lower limit of normal before treatment, a TSH that stays elevated after starting levothyroxine may be a signal that the dose needs to go up. But in patients whose TSH was already very low at diagnosis, tracking it during treatment adds nothing.8European Thyroid Journal. 2018 European Thyroid Association (ETA) Guidelines on the Diagnosis and Management of Central Hypothyroidism
Pregnancy and Central Hypothyroidism
Pregnancy substantially increases the body’s demand for thyroid hormone. For women with central hypothyroidism, this means the levothyroxine dose typically needs to rise by roughly 25 to 50% during pregnancy, and the free T4 target shifts upward as well. The European Thyroid Association guidelines suggest aiming for the upper quartile of the normal range during pregnancy, to reduce the chance that the fetus is underexposed to thyroid hormone during critical periods of brain development.9European Thyroid Journal. 2018 European Thyroid Association (ETA) Guidelines on the Diagnosis and Management of Central Hypothyroidism
This is one area where the inability to use TSH creates real anxiety for both patient and doctor. In primary hypothyroidism, a rising TSH during pregnancy is a clear distress signal. In central hypothyroidism, that signal does not exist, so vigilant free T4 monitoring every four to six weeks is essential. After delivery, the dose usually drops back toward pre-pregnancy levels, but it should be rechecked rather than simply reverted, since postpartum thyroid function can shift in unpredictable ways.
Treating Newborns and Infants
Central congenital hypothyroidism has historically been underdiagnosed in newborns, partly because most newborn screening programs are built to detect primary hypothyroidism by looking for elevated TSH, which central hypothyroidism does not produce. Recent research has pushed back against the old assumption that central congenital hypothyroidism is mild and unimportant, showing that early detection and treatment lead to substantially better neurodevelopmental outcomes.10PubMed Central. Diagnosis and Management of Central Congenital Hypothyroidism
In severe cases where the newborn’s free T4 is very low (below about 5 pmol/L), consensus guidelines recommend starting levothyroxine promptly at doses of 10 to 15 micrograms per kilogram per day, the same aggressive dosing used for severe primary congenital hypothyroidism. In milder presentations, a lower starting dose of 5 to 10 micrograms per kilogram per day is suggested to avoid the risk of overtreatment. Monitoring follows the same principle as in adults: free T4 is the guide, kept above the midpoint of the age-appropriate reference range. If TSH was already low before treatment began, there is no point in continuing to measure it.11PubMed Central. Congenital Hypothyroidism: A 2020–2021 Consensus Guidelines Update—An ENDO-European Reference Network Initiative Endorsed by the European Society for Pediatric Endocrinology and the European Society for Endocrinology
Clinicians sometimes miss central congenital hypothyroidism even in the hospital setting despite signs that something is off, such as feeding difficulties, low blood sugar, or prolonged jaundice. These symptoms overlap with many other neonatal conditions, which is part of why the diagnosis slips through. Countries that include T4 measurements in their screening panels alongside TSH catch more cases, but not all screening programs do this.
When Other Hormone Replacements Change the Equation
Central hypothyroidism rarely exists in isolation. Because the pituitary controls multiple hormones, patients often need replacement therapy for growth hormone, cortisol, sex hormones, or antidiuretic hormone alongside levothyroxine. These replacements interact with thyroid hormone in ways that can throw dosing off if they are not anticipated.
Growth hormone replacement is the most well-documented example. Growth hormone increases the conversion of T4 to T3 in peripheral tissues, which can unmask or worsen central hypothyroidism. In one study of patients starting growth hormone therapy, about 36% of those not already on levothyroxine became hypothyroid and needed to start it, while 16% of those already on levothyroxine required a dose increase.12PubMed. Unmasking of central hypothyroidism following growth hormone replacement in adult hypopituitary patients The takeaway is that thyroid function should be rechecked a few weeks after initiating or adjusting growth hormone therapy.
Estrogen therapy introduces its own wrinkle. Oral estrogen increases the liver’s production of thyroxine-binding globulin, a protein that binds T4 in the bloodstream and makes less of it available to tissues. In one clinical trial comparing oral versus transdermal estradiol in women with hypothyroidism, oral estrogen raised thyroxine-binding globulin levels substantially, and three out of ten participants in the oral group needed their levothyroxine dose increased.13PubMed. Effects of oral versus transdermal estradiol plus micronized progesterone on thyroid hormones, hepatic proteins, lipids, and quality of life in menopausal women with hypothyroidism: a clinical trial Transdermal estrogen largely bypasses the liver and does not cause this effect, which is worth knowing if you are managing both menopause and central hypothyroidism.
The Question of Adding T3
Some patients on levothyroxine alone continue to feel unwell despite having free T4 levels that look adequate on blood work. Fatigue, brain fog, and low mood are the most common lingering complaints. This has fueled longstanding interest in combination therapy, using levothyroxine alongside liothyronine (synthetic T3) to supplement both hormones directly rather than relying entirely on the body to convert T4 to T3.
A recent case series of hypothyroid patients switched from levothyroxine alone to combination LT4 plus LT3 found that total T3 levels increased and symptom burden decreased across all patients studied.14Journal of Clinical and Translational Endocrinology: Case Reports. Combination therapy with levothyroxine and liothyronine in hypothyroid patients with persistent symptoms: A case series However, case series represent the weakest level of clinical evidence, and larger controlled trials have not consistently shown that combination therapy produces measurable improvements over levothyroxine alone. Current guidelines do not endorse routine use of desiccated thyroid or combination therapy, noting that controlled studies have not clearly demonstrated enhanced objective outcomes compared with levothyroxine monotherapy.
For central hypothyroidism specifically, the evidence base on combination therapy is even thinner than it is for primary hypothyroidism. The theoretical rationale is the same, but the practical complexity is greater: monitoring becomes harder because you are now tracking both free T4 and T3, and the short half-life of T3 means blood levels fluctuate throughout the day. Most endocrinologists treat combination therapy as a trial-and-error option for patients with persistent symptoms after other causes have been ruled out, rather than as a standard first-line approach.
Formulation Matters More Than You Might Think
Levothyroxine is available as a traditional tablet, a soft gel capsule, and a liquid solution. For most people, the tablet works fine. But absorption of levothyroxine from tablets is sensitive to stomach acidity, and anything that raises gastric pH, such as proton pump inhibitors for acid reflux, or even just drinking coffee shortly before or after taking the pill, can reduce how much drug actually reaches the bloodstream.
Soft gel capsules and liquid formulations appear to sidestep this problem. Laboratory studies have shown that the soft gel capsule releases its active ingredient more consistently across varying pH levels than the tablet, and clinical studies confirmed that both the soft gel and liquid forms overcome the absorption problems caused by certain medications, coffee, and even bariatric surgery.15PubMed Central. The administration of L-thyroxine as soft gel capsule or liquid solution For patients with central hypothyroidism who are already dealing with imprecise monitoring because TSH cannot guide dosing, unpredictable absorption adds another layer of uncertainty. Switching to a non-tablet formulation can sometimes resolve what looks like a dosing problem but is actually an absorption problem.
Cardiovascular Risk and the Fine Line of Replacement
There is a real tension in central hypothyroidism management between replacing enough thyroid hormone and replacing too much. Under-replacement leaves the patient hypothyroid and exposed to the metabolic consequences of that state, including elevated cholesterol, weight gain, and fatigue. Over-replacement mimics hyperthyroidism and can cause heart rhythm disturbances, bone loss, and anxiety.
Research into central hypothyroidism and cardiovascular outcomes remains limited. Studies on cardiovascular risk in these patients are few, often small, and complicated by the difficulty of accurate biochemical diagnosis and the challenge of monitoring treatment when the normal thyroid-pituitary feedback loop is broken.16SpringerLink / Endocrine. Central hypothyroidism and its role for cardiovascular risk factors in hypopituitary patients What we do know is that hypopituitary patients in general carry elevated cardiovascular risk, and undertreated thyroid deficiency is thought to be one contributing factor. This is part of why guidelines favor targeting the mid-to-upper portion of the free T4 range rather than accepting values that are technically “normal” but sit at the low end.
In older adults or those with known coronary artery disease, however, starting doses are kept low and titration is cautious. A sudden jump in thyroid hormone can increase heart rate and oxygen demand, which a compromised heart may not tolerate. The approach is to start slow, recheck free T4 in four to six weeks, and nudge the dose up in small increments.
Immune Checkpoint Inhibitors and a Growing Patient Population
One of the fastest-growing causes of central hypothyroidism has nothing to do with pituitary tumors or genetics. Immune checkpoint inhibitors, drugs that unleash the immune system against cancer, can inflame the pituitary gland as a side effect. This immune-related pituitary inflammation, called hypophysitis, frequently knocks out several pituitary hormone axes at once. In a study tracking 83 patients on checkpoint inhibitors, central hypothyroidism appeared in 94% of those who developed hypophysitis, alongside central adrenal insufficiency in about 69%.17Endocrine-Related Cancer. Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns
As immunotherapy becomes more widely used in oncology, the number of people living with treatment-induced central hypothyroidism is rising. Unlike some other immune-related side effects of checkpoint inhibitors, pituitary damage tends to be permanent, meaning these patients will need lifelong levothyroxine replacement. The overlap with adrenal insufficiency in this group makes the safety protocol discussed earlier especially relevant: cortisol status must be evaluated and treated before levothyroxine is started, even if the presenting symptom is fatigue that seems thyroid-related.
Oncologists are increasingly aware of this complication, but it can still be missed if the focus is on tumor response rather than endocrine side effects. Symptoms like fatigue, headache, and low energy are common in cancer patients for many reasons, so pituitary inflammation can hide in plain sight. Routine hormone screening during checkpoint inhibitor therapy has become part of best practice at many cancer centers, though implementation varies.
How the Standard of Care Got Here
For most of the twentieth century, the go-to treatment for all forms of hypothyroidism was desiccated thyroid extract derived from pig thyroid glands. These preparations contain both T4 and T3 in a ratio determined by the animal’s biology rather than the patient’s needs. Two developments in the 1970s shifted practice toward levothyroxine monotherapy: the invention of the TSH radioimmunoassay revealed that many patients on desiccated thyroid were being overtreated, and the discovery that the body converts T4 to T3 on its own made single-hormone replacement seem both safer and sufficient.18PubMed Central. The History and Future of Treatment of Hypothyroidism
Ironically, the very tool that made levothyroxine monotherapy the standard, the TSH assay, is the one tool that does not work properly in central hypothyroidism. This created a situation where clinicians had an excellent medication but a poor feedback signal for adjusting it. Progress in recent decades has focused on refining the free T4 target, understanding how co-administered hormones shift thyroid balance, and recognizing that central hypothyroidism is not simply a milder version of primary hypothyroidism but a condition with its own risks and treatment pitfalls.19PubMed. Central Hypothyroidism: Advances in Etiology, Diagnostic Challenges, Therapeutic Targets, and Associated Risks